Humacyte, Inc. (HUMA) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 10 Buy, 1 Hold.
The consensus price target is $4.50 (low: $3.00, high: $6.00), representing an upside of 511.3% from the current price $0.74.
Analysts estimate Earnings Per Share (EPS) of $-1.35 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.26 vs est $-1.35 (beat +6.6%). 2025: actual $-0.26 vs est $-0.29 (beat +11.3%). Analyst accuracy: 90%.
HUMA Stock — 12-Month Price Forecast
$4.50
▲ +511.33% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Humacyte, Inc., the average price target is $4.50, with a high forecast of $6.00, and a low forecast of $3.00.
The average price target represents a +511.33% change from the last price of $0.74.
Highest Price Target
$6.00
Average Price Target
$4.50
Lowest Price Target
$3.00
HUMA Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Humacyte, Inc. in the past 3 months
EPS Estimates — HUMA
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.26
vs Est –$1.35
▲ 7.0% off
2025
Actual –$0.26
vs Est –$0.29
▲ 12.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — HUMA
66%
Analyst Accuracy
Fair
1 year compared
Actual vs Estimate
2025
Actual $0.002B
vs Est $0.003B
▼ 34.0% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
